Klotho Neurosciences (NASDAQ:KLTO) Trading Down 3.3% – What’s Next?

Klotho Neurosciences, Inc. (NASDAQ:KLTO)’s stock price dropped 3.3% during trading on Thursday . The stock traded as low as $0.44 and last traded at $0.45. Approximately 2,736,614 shares were traded during mid-day trading, a decline of 20% from the average daily volume of 3,401,634 shares. The stock had previously closed at $0.47.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Klotho Neurosciences to a “sell” rating in a research note on Saturday, July 5th.

Klotho Neurosciences Stock Performance

The stock has a market cap of $31.72 million, a P/E ratio of -1.00 and a beta of 10.05. The firm’s 50 day moving average is $0.71 and its 200 day moving average is $0.65.

Klotho Neurosciences (NASDAQ:KLTO) last posted its quarterly earnings data on Monday, August 18th. The company reported ($0.12) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Klotho Neurosciences stock. Jane Street Group LLC purchased a new stake in shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 23,364 shares of the company’s stock, valued at approximately $26,000. Jane Street Group LLC owned approximately 0.05% of Klotho Neurosciences at the end of the most recent quarter. 20.07% of the stock is owned by institutional investors.

About Klotho Neurosciences

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors.